NASDAQ:CALA Calithera Biosciences (CALA) Stock Price, News & Analysis $0.0003 +0.00 (+200.00%) As of 10/23/2026 12:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About Calithera Biosciences Stock (NASDAQ:CALA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Calithera Biosciences alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000350-Day Range N/A52-Week Range$0.0001▼$0.0010Volume347 shsAverage Volume713 shsMarket Capitalization$1.16 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calithera Biosciences, Inc. was a clinical-stage biopharmaceutical company focused on developing small-molecule therapies that target cancer metabolism. The company sought to exploit metabolic dependencies in tumor cells to create treatments for cancer, with research programs designed for use both as standalone therapies and in combination with existing medicines. Calithera’s lead investigational product was telaglenastat (also known as CB-839), an oral inhibitor of glutaminase, an enzyme involved in glutamine metabolism. The drug was evaluated in clinical studies for several types of cancer, including renal cell carcinoma and triple-negative breast cancer. The company also pursued additional oncology programs involving other metabolic and immune-related targets. Founded in 2010 and headquartered in South San Francisco, California, Calithera was led for much of its operating history by co-founder and former Chief Executive Officer Susan Molineaux. The company conducted development activities through clinical research and collaborations with pharmaceutical and biotechnology partners. After discontinuing key development programs and reducing operations, Calithera pursued a wind-down and bankruptcy proceedings, and it is no longer an active operating biotechnology company.AI Generated. May Contain Errors. Read More Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CALA Stock News HeadlinesCalithera Biosciences (NASDAQ:CALA) Stock Breaks Above 50 Day Moving Average - Here's What HappenedOctober 20, 2026 | americanbankingnews.comCalithera Biosciences Inc (CALA)November 23, 2024 | investing.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 25 at 1:00 AM | Porter & Company (Ad)Primecap Management Portfolio Exposed: Top Holdings RevealedApril 26, 2024 | msn.comChristina CalaAugust 12, 2023 | npr.orgNCalithera Biosciences cancels special meeting due to lack of quorumJune 29, 2023 | seekingalpha.comCALA - Calithera Biosciences, Inc.May 31, 2023 | finance.yahoo.comCalithera Biosciences, Inc.: Calithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 20, 2023 | finanznachrichten.deSee More Headlines CALA Stock Analysis - Frequently Asked Questions How have CALA shares performed this year? Calithera Biosciences' stock was trading at $0.0001 on January 1st, 2026. Since then, CALA stock has increased by 200.0% and is now trading at $0.0003. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) announced its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($3.00) earnings per share for the quarter, topping the consensus estimate of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter. When did Calithera Biosciences' stock split? Shares of Calithera Biosciences reverse split before market open on Wednesday, June 15th 2022.The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Bank of America (BAC), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). Company Calendar Last Earnings11/08/2021Today10/25/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CALA CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees60Year Founded2010Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares3,860,000Free Float4,550,000Market Cap$1.16 thousand OptionableNot Optionable Beta-1.52 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:CALA) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calithera Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
